These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15793188)

  • 41. The predictive value of inflammatory activity and markers of the adipo-insular axis on restenosis in patients with type 2 diabetes.
    Hage C; Grip L; Malmberg K; Rydén L; Wallander M; Saleh N
    Diab Vasc Dis Res; 2011 Apr; 8(2):143-9. PubMed ID: 21562066
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does a well developed collateral circulation predispose to restenosis after percutaneous coronary intervention? An intravascular ultrasound study.
    Perera D; Postema P; Rashid R; Patel S; Blows L; Marber M; Redwood S
    Heart; 2006 Jun; 92(6):763-7. PubMed ID: 16216859
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.
    Ota H; Mahmoudi M; Kitabata H; Torguson R; Chen F; Satler LF; Suddath WO; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2015 Mar; 16(2):84-9. PubMed ID: 25870152
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repeat adverse events long after percutaneous coronary revascularization in diabetics.
    Cavallero E; Biondi-Zoccai G; Mazzanti A; Moretti C; Sciuto F; Omedé P; Siliquini R; Chiadò S; Trevi GP; Sheiban I
    Minerva Cardioangiol; 2010 Feb; 58(1):23-34. PubMed ID: 20145593
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry.
    Ortolani P; Balducelli M; Marzaroli P; Piovaccari G; Menozzi A; Guiducci V; Sangiorgio P; Tarantino F; Geraci G; Castriota F; Tondi S; Saia F; Cooke RM; Guastaroba P; Grilli R; Marzocchi A; Maresta A
    Circulation; 2008 Feb; 117(7):923-30. PubMed ID: 18250265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
    Naganuma T; Chieffo A; Meliga E; Capodanno D; Park SJ; Onuma Y; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Costopoulos C; Kim YH; Buszman PP; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capranzano P; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1242-9. PubMed ID: 24355114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stenting of unprotected left main coronary artery in patients with low preoperative risk of coronary artery bypass grafting.
    Dudek D; Heba G; Giszterowicz D; Rzeszutko Ł; Legutko J; Bartuś S; Chyrchel M; Dubiel JS
    Kardiol Pol; 2006 Sep; 64(9):929-36; discussion 937-8. PubMed ID: 17054024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sex-specific outcomes following revascularization with zotarolimus-eluting stents: comparison of angiographic and late-term clinical results.
    Brown RA; Williams M; Barker CM; Mauri L; Meredith IT; Fajadet J; Wijns W; Leon MB; Kandzari DE
    Catheter Cardiovasc Interv; 2010 Nov; 76(6):804-13. PubMed ID: 20815043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Body Mass Index and Repeat Revascularization After Percutaneous Coronary Intervention: A Meta-analysis.
    Wang ZJ; Gao F; Cheng WJ; Yang Q; Zhou YJ
    Can J Cardiol; 2015 Jun; 31(6):800-8. PubMed ID: 25921864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical presentation and outcome of patients hospitalized for symptomatic in-stent restenosis treated by percutaneous coronary intervention: comparison between drug-eluting stents and bare-metal stents.
    De Labriolle A; Bonello L; Lemesle G; Steinberg DH; Roy P; Xue Z; Kaneshige K; Suddath WO; Satler LF; Kent KM; Pichard AD; Lindsay J; Waksman R
    Arch Cardiovasc Dis; 2009 Mar; 102(3):209-17. PubMed ID: 19375675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term clinical outcomes after intravascular brachytherapy for instent restenosis and de novo coronary artery lesions in percutaneous coronary intervention.
    Ho HH; Kwok OH; Jim MH; Siu CW; Pong V; Chow WH
    Cardiovasc Revasc Med; 2011; 12(3):152-157. PubMed ID: 21640933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes.
    Roguin A; Koch W; Kastrati A; Aronson D; Schomig A; Levy AP
    Diabetes Care; 2003 Sep; 26(9):2628-31. PubMed ID: 12941730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): immediate and long-term results.
    Rodriguez A; Rodríguez Alemparte M; Fernández Pereira C; Sampaolesi A; da Rocha Loures Bueno R; Vigo F; Obregón A; Palacios IF;
    Am J Med; 2005 Jul; 118(7):743-51. PubMed ID: 15989908
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Angiographic and clinical outcome of percutaneous coronary intervention for in-stent restenosis of bifurcated lesions.
    Coroleu SF; De Vita M; Burzotta F; Trani C; Porto I; Niccoli G; Leone AM; Tommasino A; Talarico GP; Schiavoni G; Crea F
    EuroIntervention; 2012 Oct; 8(6):701-7. PubMed ID: 23086788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ambulatory blood pressure variability is associated with restenosis after percutaneous coronary intervention in normotensive patients.
    Cay S; Cagirci G; Demir AD; Balbay Y; Erbay AR; Aydogdu S; Maden O
    Atherosclerosis; 2011 Dec; 219(2):951-7. PubMed ID: 22005197
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.
    Brener SJ; Steinhubl SR; Berger PB; Brennan DM; Topol EJ;
    J Invasive Cardiol; 2007 Jul; 19(7):287-90. PubMed ID: 17620671
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
    Rodriguez AE; Vigo CF; Delacasa A; Mieres J; Fernandez-Pereira C; Bernardi V; Bettinoti M; Rodriguez-Granillo AM; Rodriguez-Granillo G; Santaera O; Curotto V; Rubilar B; Tronge J; Palacios IF; Antoniucci D;
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):335-42. PubMed ID: 20824769
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registry.
    Iversen AZ; Pedersen SH; Joens C; Mogelvang R; Galatius S; Galloe A; Abildgaard U; Hansen PR; Madsen JK; Jensen JS
    J Invasive Cardiol; 2011 Jan; 23(1):21-6. PubMed ID: 21183766
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The -374T/A variant of the rage gene promoter is associated with clinical restenosis after coronary stent placement.
    Falcone C; Emanuele E; Buzzi MP; Ballerini L; Repetto A; Canosi U; Mazzucchelli I; Schirinzi S; Sbarsi I; Boiocchi C; Cuccia M
    Int J Immunopathol Pharmacol; 2007; 20(4):771-7. PubMed ID: 18179750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials.
    Cutlip DE; Chhabra AG; Baim DS; Chauhan MS; Marulkar S; Massaro J; Bakhai A; Cohen DJ; Kuntz RE; Ho KK
    Circulation; 2004 Sep; 110(10):1226-30. PubMed ID: 15337693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.